Advice
Following an abbreviated submission
Emtricitabine/tenofovir disoproxil 200 mg/245 mg tablet (Truvada) is accepted for use in NHS Scotland for the treatment of Human Immunodeficiency Virus (HIV-1) infected adults in combination with other antiretroviral medicinal products. Both constituents are nucleoside reverse transcriptase inhibitors. The demonstration of the benefit of the combination emtricitabine and tenofovir disoproxil fumarate in antiretroviral therapy is based solely on studies performed in treatment-naïve patients.
Download detailed advice28KB (PDF)
Medicine details
- Medicine name:
- Emtricitabine/tenofovir disoproxil 200 mg / 245 mg tablet (Truvada®)
- SMC ID:
- 237/06
- Indication:
- HIV
- Pharmaceutical company
- Gilead Sciences Ltd
- BNF chapter
- Infections
- Submission type
- Abbreviated
- Status
- Accepted
- Date advice published
- 13 February 2006